JPMorgan Chase & Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

JPMorgan Chase & Co. boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 17.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 297,810 shares of the specialty pharmaceutical company's stock after buying an additional 44,414 shares during the period. JPMorgan Chase & Co. owned approximately 0.54% of Supernus Pharmaceuticals worth $10,769,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Exchange Traded Concepts LLC lifted its position in Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock valued at $800,000 after purchasing an additional 560 shares during the last quarter. HighTower Advisors LLC grew its position in Supernus Pharmaceuticals by 7.3% in the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after acquiring an additional 624 shares in the last quarter. Bridge City Capital LLC increased its stake in Supernus Pharmaceuticals by 0.8% during the fourth quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock worth $3,435,000 after acquiring an additional 761 shares during the last quarter. Rhumbline Advisers raised its position in Supernus Pharmaceuticals by 0.5% during the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock valued at $6,236,000 after purchasing an additional 800 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Supernus Pharmaceuticals by 0.7% in the 4th quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock valued at $3,920,000 after purchasing an additional 800 shares during the last quarter.

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 over the last quarter. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Up 0.2 %

SUPN traded up $0.05 during trading hours on Friday, reaching $30.76. 476,313 shares of the company's stock traded hands, compared to its average volume of 493,976. The firm has a 50-day moving average price of $32.76 and a 200 day moving average price of $35.03. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm has a market capitalization of $1.72 billion, a PE ratio of 28.75 and a beta of 0.90.

Analyst Ratings Changes

Several analysts recently weighed in on the company. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.